We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CBER Plan Aims to Speed AE Analysis, Reduce Phase III Failures
CBER Plan Aims to Speed AE Analysis, Reduce Phase III Failures
June 6, 2012
FDA’s Center for Biologics Evaluation and Research (CBER) hopes to speed studies of biologic adverse events within the next five years by using the FDA’s Mini-Sentinel postmarket surveillance pilot in partnership with other government agencies and private organizations.